EMEmilie Michel

Emilie Michel

*This is an algorithmically generated author record based on publicly available information.

Emilie Michel has a total of 13 co-authors. Here are the top co-authors by number of shared publications:

  • Alain Viari

    Bioinformatics Platform Gilles Thomas, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1 , Synergie Lyon Cancer Fondation, 69008 Lyon

    1 shared publication
  • Christophe Caux

    Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, INSERM U1052, CNRS UMR5286, Université Claude Bernard Lyon 1

    1 shared publication
  • Jenny Valladeau-Guilemond

    Centre de Recherche en Cancérologie de Lyon (CRCL), UMR INSERM U1052 CNRS 5286, Lyon, France

    1 shared publication
  • Juliette Martin

    Laboratory of Biology and Modeling of the Cell, Ecole Normale Supérieure de Lyon, CNRS UMR 5239, Inserm U1293, University Claude Bernard Lyon 1, Lyon, France

    1 shared publication
  • Laurie Tonon

    Synergie Lyon Cancer, Plateforme de bioinformatique « Gilles Thomas », Lyon, France

    1 shared publication
  • Nicolas Chuvin

    ErVaccine technologies, Lyon, France

    1 shared publication

Latest Publications

  • Open Access

    Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy

    by Paola Bonaventura, Vincent Alcazer, Virginie Mutez, Laurie Tonon, Juliette Martin, Nicolas Chuvin, Emilie Michel, Rasha E. Boulos, Yann Estornes, Jenny Valladeau-Guilemond, et al.

    Human endogenous retroviruses (HERVs) represent 8% of the human genome. HERV products may represent tumor antigens relevant for cancer immunotherapy. We developed a bioinformatic approach to identify shared CD8 + T cell epitopes derived from cancer-associated HERVs in solid tumors. Six candidates among the most commonly shared HLA-A2 epitopes with evidence of translation were selected for immunological evaluation. In vitro priming assays confirmed the immunogenicity of these epitopes, which induced high-avidity CD8 + T cell clones. These T cells specifically recognize and kill HLA-A2 + tumor cells presenting HERV epitopes on HLA molecules, as demonstrated by mass spectrometry. Furthermore, epitope-specific CD8 + T cells were identified by dextramer staining among tumor-infiltrating lymphocytes from HLA-A2 + patients with breast cancer. Last, we showed that HERV-specific T cells lyse patient-derived organoids. These shared virus-like epitopes are of major interest for the development of cancer vaccines or T cell–based immunotherapies, especially in tumors with low/intermediate mutational burden.